



**SIEMENS**

[usa.siemens.com/plasma-proteins](http://usa.siemens.com/plasma-proteins)

# Enabling Early Detection of Renal Function Decline

N Latex Cystatin C Assay

# Diagnosing the Silent Threat: Chronic Kidney Disease

Chronic kidney disease is a major public-health problem across the world. In the U.S. and Western Europe, the incidence has tripled since 1990, a trend that seems likely to continue due to the increasing incidence of diabetes and hypertension—the major causes of kidney failure in today’s aging population.<sup>1</sup>

Data from the USRDS annual report shows that the number of patients treated for end-stage renal disease (ESRD) is 10 times higher than in 1980, with more than 678,000 in the U.S. alone.<sup>2</sup>


Intelligent laboratory-testing solutions not only provide valuable information for monitoring kidney disease, but also contribute substantially to improved patient outcomes and reduced healthcare costs.

## Kidney disease is painless

Renal disease often progresses undetected, because kidney impairment does not cause pain. This is why, for so many patients, kidney disease is not diagnosed until they show symptoms of an advanced stage of the disease. In the early stages of disease, laboratory testing is the most efficient and sensitive way to detect reduction in renal function.

**Today, chronic kidney disease can be significantly detained if diagnosed early enough.**

Laboratory testing for kidney disease can therefore have a crucial impact on patient management. It can reduce the risk of developing end-stage renal disease (requiring dialysis or transplantation) and cardiovascular disease (CVD), the leading cause of mortality in chronic kidney disease patients (Figure 1).



**Figure 1.** Projected growth of prevalent ESRD populations, by modality.<sup>3</sup>

Counts projected using a Markov model. Original projection uses data through 2000; new projection uses data through 2005.

## GFR and chronic kidney disease

According to KDIGO\* guidelines published in January 2013, the assessment of the glomerular filtration rate (GFR) is an important step during the continuum of kidney disease (Figure 2).

Definition of chronic kidney disease:<sup>1</sup>

- GFR <60 mL/min/1.73 m<sup>2</sup> for ≥3 months, or
- Kidney damage for ≥3 months (structural or functional abnormalities; e.g., increased albumin excretion)

A reliable and sensitive method for GFR assessment is crucial to diagnose CKD at an early stage, because strategies to improve outcomes are more successful with earlier treatment.

Today, determination of serum creatinine is the most widely used method for estimating GFR. However, the creatinine level is strongly related to the patient’s muscle mass and must be corrected for weight and age (e.g., using the Cockcroft-Gault formula) to allow accurate interpretation. Furthermore, creatinine is increasingly secreted by renal tubules with decreasing renal function. As a result, serum creatinine increases only when the full capacity of this alternative route of elimination is reached (the creatinine-blind range).


## Advanced GFR determination with cystatin C

Cystatin C is a nonglycated, low-molecular-weight (13 kDa) protein that is synthesized by all nucleated cells. It is produced at a constant rate regulated by a housekeeping gene.<sup>5</sup>

Cystatin C is freely filtered by the glomerulus, and there is no tubular secretion or any extrarenal elimination. In addition, cystatin C is not affected by muscle mass, diet, gender, or inflammation.

Due to these factors, cystatin C shows increased sensitivity to renal dysfunction compared to serum creatinine, especially in the early stage of kidney disease characterized by a mild reduction of GFR.

After glomerular filtration, cystatin C is reabsorbed and metabolized by the proximal tubule cells, resulting in a very low concentration in urine under normal conditions. However, an increase in urinary cystatin C may indicate a tubular injury or dysfunction.<sup>5</sup>



**Figure 2.** Glomerular filtration rate (GFR) describes the functional capacity of the kidneys and is used to define the severity of kidney dysfunction.

\*KDIGO: Kidney Disease Improving Global Outcomes

# Cystatin C: the More Sensitive Alternative for Estimating GFR

There are multiple studies and formulas available to calculate the estimated glomerular filtration rate (eGFR) from creatinine or cystatin C alone or in combination.

However, cystatin C offers clear advantages over serum creatinine and creatinine-based GFR formulas for a sensitive and reliable diagnosis of decreased GFR.

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2012 formula for determination of eGFR from cystatin C is shown in Table 1.

## Determining cystatin C is now recommended in international guidelines

For the first time, the relevance of determining cystatin C for diagnosis for CKD is now included in the international KDIGO guidelines. Well-validated equations based on cystatin C and the combination of cystatin C and creatinine are provided.

In addition, KDIGO guidelines recommend adding cystatin C in special clinical settings where creatinine alone may be less accurate, as well as for confirmation of CKD, particularly in GFR stage G3a between 45–59 mL/min/1.73 m<sub>2</sub>.

**Table 1.** KDIGO/CKD-EPI 2012 cystatin C equation for adult GFR estimation.

	Serum Cystatin C	Equation for Estimating GFR
Male or female	≤0.8 mg/L	$133 \times (\text{SCysC}/0.8)^{-0.499} \times 0.996^{\text{Age}} [ \times 0.932 \text{ if female} ]$
Male or female	>0.8 mg/L	$133 \times (\text{SCysC}/0.8)^{-1.328} \times 0.996^{\text{Age}} [ \times 0.932 \text{ if female} ]$

**Table 2.** Classification of chronic kidney disease based on GFR and cystatin C level (60-year-old male patient).

Stage	GFR (mL/min/1.73 m <sub>2</sub> )	Cystatin C (mg/L)	Description
1	≥90	<0.92	Normal or elevated GFR
2	60–89	0.93–1.26	Mildly decreased GFR
3a	45–59	1.27–1.56	Mild to moderate GFR reduction
3b	30–44	1.5–2.13	Moderate to severe GFR reduction
4	15–29	2.14–3.55	Severely decreased GFR
5	<15	>3.56	Kidney failure

Cystatin C/GFR conversion based on CKD-EPI cystatin C 2012 equation.

## Alternative GFR estimation from cystatin C

The IFCC SD Working Group on Standardization of Cystatin C has developed the Caucasian, Asian, Pediatric, and Adult (CAPA) equation for converting cystatin C values to body-surface-adjusted eGFR.<sup>6</sup> The utility of this formula was validated in a population of 4690 subjects using seven assays adjusted to the international cystatin C calibrator ERM-DA471/IFCC and is shown in Figure 3.

$$\text{eGFR}_{\text{Cys C}} (\text{mL}/\text{min}/1.73 \text{ m}_2) = 130 \times \text{Cystatin C}^{-1.069} \times \text{age}^{-0.117} - 7$$

**Figure 3.** CAPA equation for eGFR calculation based on IFCC standardized cystatin C assay.

## New Internationally Certified Cystatin C Reference Material<sup>6</sup>

The IFCC Working Group on Standardization of Cystatin C, in collaboration with the Institute for Reference Materials and Measurements and Siemens Healthcare Diagnostics Products GmbH, developed the first internationally certified reference material: ERM-DA471/IFCC. The 2012 KDIGO Guidelines recommend that clinical laboratories that measure cystatin C should use an assay with calibration traceable to the international standard reference material.

# Cystatin C for GFR Determination in Clinical Routine: Patients Who Benefit Most

## Patients with suspected to moderate GFR reduction<sup>7</sup>

- GFR may decline by as much as 50% of normal before serum creatinine increases to levels above the reference range.
- A meta-analysis of 46 papers that compared a GFR reference method against cystatin C and serum creatinine concluded cystatin C to be clearly superior, providing a higher diagnostic efficiency (AUC 0.926 vs. 0.837 for serum creatinine). The higher AUC for cystatin C is a result of the higher sensitivity of cystatin C for mild to moderate renal dysfunction.

## Elderly patients<sup>8</sup>

- Decrease in renal function is a normal process of aging. In parallel, muscle mass also decreases with aging, further reducing the sensitivity of creatinine.
- Decrease in GFR often requires adjustment of drug dosing.
- GFR (inulin clearance) in elderly patients was significantly reduced compared to a younger control group. While creatinine levels did not differ, cystatin C levels were significantly higher in the elderly and more closely correlated to GFR.

## Children and young infants<sup>9</sup>

- In childhood, the age and muscle-mass dependency of serum creatinine complicates GFR assessment, even when body-length-to-creatinine ratios are used.
- EDTA-clearance determination in 225 children showed significantly higher correlation to cystatin C compared to the Schwartz formula ( $r = 0.765$  vs.  $0.706$ ) and higher diagnostic efficiency (AUC 0.943 vs. 0.917).

## Patients with diabetes and hypertension<sup>10</sup>

- Microalbuminuria and a decrease in GFR are predictors for progression to overt nephropathy.
- In diabetic patients, cystatin C was more closely correlated to Cr-EDTA-determined GFR ( $r = 0.84$ ) than creatinine ( $r = 0.70$ ).
- The diagnostic efficiency was 90% for cystatin C, 77% for creatinine, and 85% for the Cockcroft-Gault formula.

## Acute renal failure<sup>11</sup>

- Incidence of acute renal failure is still high (30% in intensive care, 5% in hospital). Mortality is lower if diagnosed early.
- Current diagnosis by an increase in serum creatinine (50 or 100%) comes relatively late.
- Corresponding increases in cystatin C are observed 1 to 2 days earlier.

## Kidney transplant recipients<sup>12</sup>

- Due to tubular secretion, serum creatinine overestimates GFR after transplantation by 30–40% compared to EDTA clearance, suggesting a false-normal GFR in approximately 25% of renal transplant patients.
- Cystatin C slightly underestimates GFR (by 14%); no false-normal GFR estimates were observed with cystatin C.

## Patients with liver disease<sup>13</sup>

- Liver cirrhosis is often accompanied by functional renal failure.
- In cirrhotic patients, creatinine overestimates GFR because of muscle wasting syndrome and an impaired conversion of creatine to creatinine.
- In 42 liver cirrhosis patients with reduced GFR (inulin clearance), sensitivity was 86% for cystatin C compared to 29% for creatinine.



# Add Sensitivity and Reliability in Daily GFR Assessment with the N Latex Cystatin C Assay from Siemens Healthcare Diagnostics

## Cystatin C: the more sensitive diagnostic test alternative to creatinine for estimating glomerular filtration rate (GFR)

	Cystatin C	Creatinine
<b>Filtration-independent elimination</b>	<p><b>No tubular secretion; sensitive in the creatinine-blind range<sup>5</sup></b></p> <ul style="list-style-type: none"> <li>Higher sensitivity in early disease</li> </ul>	<p><b>In early disease, tubular secretion compensates for the decline of glomerular filtration</b></p> <ul style="list-style-type: none"> <li>Creatinine-blind range; creatinine levels increase only if more than 50% of renal function is lost</li> <li>MDRD<sup>†</sup> or Cockcroft-Gault formula cannot compensate for this limitation</li> </ul>
<b>Influence of age, sex, and muscle mass</b>	<p><b>Independent of age, sex, and muscle mass<sup>5</sup></b></p> <ul style="list-style-type: none"> <li>Constant relationship between cystatin C and GFR at 1 year of age and older</li> <li>Single reference range: 0.49–1.19 mg/L<sup>‡</sup> in children and adults</li> <li>Sensitive detection of declining GFR with aging</li> <li>Reliable in patients with spina bifida, paralysis, amputations, etc.</li> </ul>	<p><b>Dependent on age, sex, and muscle mass</b></p> <ul style="list-style-type: none"> <li>Different relationships between creatinine and GFR; between men and women; in children, adults, and elderly; and in patients with low and high muscle mass</li> <li>Different reference ranges for interpretation</li> <li>Correction for age, sex, race, and weight in GFR estimation formulas</li> <li>Due to declining muscle mass in old age, lower sensitivity to loss of renal function with aging</li> <li>Not suited for patients with grossly abnormal muscle mass</li> </ul>
<b>Correlation to GFR reference methods</b>	<p><b>High correlation to GFR reference methods;<sup>5</sup> high correlation to GFR decline</b></p> <ul style="list-style-type: none"> <li>High reliability and accuracy</li> </ul>	<p><b>Correlation to GFR reference methods less narrow, especially in normal or only slightly abnormal GFR</b></p> <ul style="list-style-type: none"> <li>Limited reliability; lower sensitivity</li> </ul>
<b>Influence of liver disease</b>	<p><b>Not influenced by liver disease or creatinine intake; may be influenced by high-dose steroid therapy or thyroid dysfunction</b></p>	<p><b>Strongly influenced by liver disease; dependent on creatinine (i.e., protein) intake</b></p>
<b>Effect of analytical interferences</b>	<p><b>No analytical interferences known</b></p>	<p><b>Many analytically interfering factors (e.g., bilirubin, ascorbic acid, various drugs) for common analytical methodologies</b></p>

<sup>†</sup>MDRD: Modification of Diet in Renal Disease

<sup>‡</sup>Recommended U.S. population reference range for N Latex Cystatin C assay standardized to ERM-DA471/IFCC reference.

### Assay characteristics

- Suitable for both serum and plasma specimens
- No need for urine collection
- Low imprecision (total CV <5%)
- Latex-enhanced reagent for high sensitivity and lot-to-lot reproducibility
- Broad initial measuring ranges cover the entire physiological range of cystatin C; BN<sup>™</sup> Systems: 0.27–9.4 mg/L
- Excellent linearity
- Closer correlation than creatinine to GFR reference methods such as Cr<sup>51</sup>-EDTA clearance<sup>7</sup>
- Runs on BN<sup>™</sup> II and BN ProSpec<sup>®</sup> Systems in full random-access mode
- IFCC standardization with only Siemens reagents on the Siemens nephelometer systems met IFCC standardization specifications in a multicenter study published in 2017.<sup>14</sup>

### Interpretation of cystatin C

#### Reference range for BN Systems: 0.49–1.19 mg/L<sup>‡</sup> cystatin C

Cystatin C is elevated in the newborn, but with maturation of kidney function over the first year, cystatin C levels decrease and reach adult levels at the end of the first year of life.

The age-related decline in GFR is considered part of normal aging (~10 mL/min per decade from 30 years). However, detection of reduced GFR in the elderly is important for prediction of adverse outcomes or drug dosage adjustments. In contrast to creatinine, the relationship between cystatin C and GFR does not change with aging.<sup>8</sup>

#### References:

- Levey AS, Coresh J, Balk E, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. *Ann Intern Med.* 2003;139:137-47.
- United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016.
- USRDS/Gilbertson projection. Presented at ASN 2007, San Francisco, CA.
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Official Journal of the International Society of Nephrology.* 2013;3:1.

- Newman DJ. Cystatin C. *Ann Clin Biochem.* 2002;39:89-104.
- Grubb A, et al. *Clin Chem Lab Med.* 2010;48:1619-21.
- Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. *Am J Kidney Dis.* 2002;40:221–26.
- Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. *Am J Kidney Dis.* 2001;37:79-83.
- Filler G, Priem F, Lepage N, et al. β-Trace protein, cystatin C, β2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. *Clin Chem.* 2002;48:729-36.
- Mussap M, Dalla Vestra M, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. *Kidney Int.* 2002;61:1453-61.
- Hergert-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C. *Kidney Int.* 2004;66:1115-22.
- Le Bricon T, Thervet E, Froissart M, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. *Clin Chem.* 2000;46:1206-7.
- Woitak RP, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. *Clin Chem.* 2000;46:712–15.
- Bargnoux A, et al. Multicenter evaluation of cystatin C measurement after assay standardization. *Clin Chem.* 2017; 63:833-841.

### Siemens Renal Disease Management Panel

- Cystatin C in serum or plasma for GFR determination
- Albumin, IgG, and α1-microglobulin in urine for assessment of glomerular and tubular nephropathy

On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this brochure are available through the Siemens sales organization worldwide. Availability and packaging may vary by country and is subject to change without prior notice. Some/All of the features and products described herein may not be available in the United States.

The information in this document contains general technical descriptions of specifications and options as well as standard and optional features, which do not always have to be present in individual cases.

Siemens reserves the right to modify the design, packaging, specifications, and options described herein without prior notice. Please contact your local Siemens sales representative for the most current information.

Note: Any technical data contained in this document may vary within defined tolerances. Original images always lose a certain amount of detail when reproduced.

BN II, BN ProSpec, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. An N Latex Cystatin C assay standardized to ERM-DA471/IFCC reference is not available for sale in the U.S. Please contact your local representative for availability.

#### **Siemens Healthineers Headquarters**

Siemens Healthcare GmbH  
Henkestr. 127  
91052 Erlangen  
Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com

#### **Local Contact Information**

Siemens Healthcare Diagnostics Inc.  
Laboratory Diagnostics  
511 Benedict Avenue  
Tarrytown, NY 10591-5005  
USA  
Phone: +1-888-826-9702  
usa.siemens.com/healthineers